A Phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778, 123 in patients with solid malignancies

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 3894-3903

  Britten, Carolyn D ^a   Rowinsky, Eric K ^a   Patnaik, Amita ^a   McCreery, Heather ^a   Soignet, Steven ^b   Pezzuli, Sandy ^b   Spriggs, David ^b   Yao, Siu Long ^c   Deutsch, Paul ^c   Lee, Yih ^c   Lobell, Robert B ^c   Mazina, Kathryn E ^c  

^a CTRC Institute for Drug Development   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; L 778123; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; FATIGUE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MALE; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PRENYLATION; PRIORITY JOURNAL; PROTEIN MODIFICATION; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA; VISUAL DISORDER;

ADULT; ALKYL AND ARYL TRANSFERASES; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; IMIDAZOLES; MALE; METABOLIC CLEARANCE RATE; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA;

EID: 0035678051     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
2. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
3. Farnesyltransferase inhibitors: Targeting the molecular basis of cancer
4. p21ras is modified by a farnesyl isoprenoid
5. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
6. Farnesol modification of Kirsten-ras exon 4B is essential for transformation
7. Ras oncogenes in human cancer: A review
8. Regulators and effectors of ras proteins
9. Function and regulation of ras
10. Ras proto-oncogene activation in human malignancy
11. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
12. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho
13. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
14. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
15. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F, and alter the association of CENP-E with the microtubules
16. Noncompartmental pharmacokinetic analysis
17. HSDJ, a human homolog of DnaJ, is farnesylated and is involved in protein import into mitochondria
18. Pharmacodynamics
19. Phase I trial of the farnesyl protein transferase inhibitor L-778, 123 on a 14- or 28-day dosing schedule
20. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors
21. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor R115777
22. Cardiac K+ channels and drug-acquired long QT syndrome
23. A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
24. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
25. Photoreceptors and retinal pigment epithelium; transduction and renewal mechanisms
26. K-, and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors